fluorouracil has been researched along with Agranulocytosis in 39 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 9.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 9.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 7.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 7.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 7.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Five of 39 (13%) women treated with adjuvant combination chemotherapy plus levamisole immunotherapy after mastectomy for Stage II or III breast cancer developed levamisole-induced granulocytopenia." | 7.66 | Mechanisms of levamisole-induced granulocytopenia in breast cancer patients. ( Brunskill, DE; Herbick, JM; Mansell, PW; McKinney, EC; Miller, AM; Padgett, DC; Silverman, MA; Sugarbaker, EV; Thompson, JS; Vogel, CL, 1980) |
| "To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 6.67 | Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 5.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor." | 5.08 | Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 5.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 3.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| " We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients." | 3.72 | FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 3.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 3.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Five of 39 (13%) women treated with adjuvant combination chemotherapy plus levamisole immunotherapy after mastectomy for Stage II or III breast cancer developed levamisole-induced granulocytopenia." | 3.66 | Mechanisms of levamisole-induced granulocytopenia in breast cancer patients. ( Brunskill, DE; Herbick, JM; Mansell, PW; McKinney, EC; Miller, AM; Padgett, DC; Silverman, MA; Sugarbaker, EV; Thompson, JS; Vogel, CL, 1980) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "39 adult cancer patients were enrolled with advanced/refractory disease not amenable to established treatments, PS | 2.69 | A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. ( Barbet, N; Buuren, IV; Capdeville, R; Choi, L; de Vries, EG; Dumez, H; Groen, HJ; Muskiet, F; Oosterom, AT; Paridaens, R; Seeghers, M; Uges, DR; van der Graaf, WT, 2000) |
| "Renal cell carcinoma is a common neoplasm that is often refractory to treatment." | 2.68 | A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. ( Blumenstein, BA; Crawford, ED; Elias, L; Flanigan, RC; Goodwin, JW; Kish, J; Lowe, BA; Wade, JL, 1996) |
| "To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 2.67 | Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994) |
| "Grade 3-4 toxicities included oral mucositis in 19 patients, granulocytopenia in 16, fatigue in 8, and diarrhea in 3." | 2.67 | Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JJ; Belt, RJ; Dakhil, SR; Dubovsky, D; Graham, S; Levin, B; Pazdur, R; Pilat, S; Winn, R, 1992) |
| " The reduction in PMN was dose-dependent with a dosage of 200 mg/kg body weight of 5-FU, causing suppression of PMN to almost undetectable levels." | 1.29 | The effect of 5-fluorouracil treatment of chicks: a cell depletion model for the study of avian polymorphonuclear leukocytes and natural host defenses. ( Corrier, DE; DeLoach, JR; Hargis, BM; Kogut, MH; Tellez, G, 1993) |
| "Neutropenic enterocolitis is a recognized complication of immunosuppression or chemotherapy for leukemia." | 1.28 | Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. ( de Vries, EJ; Johnson, JT; Petruzzelli, GJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (30.77) | 18.7374 |
| 1990's | 16 (41.03) | 18.2507 |
| 2000's | 8 (20.51) | 29.6817 |
| 2010's | 3 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, T | 1 |
| Yamashita, K | 1 |
| Sato, T | 1 |
| Ema, A | 1 |
| Naito, M | 1 |
| Watanabe, M | 1 |
| Zhang, JD | 1 |
| Shao, ZY | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Huang, HY | 1 |
| Jiang, ZF | 1 |
| Wang, T | 1 |
| Zhang, SH | 1 |
| Bian, L | 1 |
| Cao, Y | 1 |
| Wu, SK | 1 |
| Song, ST | 1 |
| Ikeda, T | 1 |
| Ishibashi, H | 1 |
| Fujisaki, R | 1 |
| Yamazaki, M | 1 |
| Wakame, K | 1 |
| Kosuna, K | 1 |
| Yamaguchi, H | 1 |
| Ono, Y | 1 |
| Abe, S | 1 |
| WOLBERG, WH | 1 |
| CURRERI, AR | 1 |
| PAGE, AR | 1 |
| MCCAFFERY, JF | 1 |
| Di Lorenzo, G | 1 |
| Autorino, R | 1 |
| Giordano, A | 1 |
| Giuliano, M | 1 |
| D'Armiento, M | 1 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Haller, DG | 1 |
| Catalano, PJ | 1 |
| Macdonald, JS | 2 |
| O'Rourke, MA | 1 |
| Frontiera, MS | 1 |
| Jackson, DV | 1 |
| Mayer, RJ | 1 |
| Guan, ZZ | 1 |
| Vogel, CL | 2 |
| Smalley, RV | 2 |
| Raney, M | 1 |
| Krauss, S | 2 |
| Carpenter, J | 2 |
| Velez-Garcia, E | 1 |
| Fishkin, E | 1 |
| Raab, S | 1 |
| Moore, MR | 1 |
| Stagg, M | 1 |
| Silverman, MA | 1 |
| Mansell, PW | 1 |
| Miller, AM | 1 |
| Thompson, JS | 1 |
| Herbick, JM | 1 |
| Brunskill, DE | 1 |
| Padgett, DC | 1 |
| McKinney, EC | 1 |
| Sugarbaker, EV | 1 |
| McCracken, JD | 1 |
| Ray, P | 1 |
| Heilbrun, LK | 1 |
| Vaitkevicius, VK | 1 |
| Saiki, JH | 1 |
| Rivkin, SE | 1 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Sato, H | 1 |
| Oh, H | 1 |
| Cho, R | 1 |
| Nakamura, H | 1 |
| Asai, T | 1 |
| Leichman, CG | 1 |
| Fleming, TR | 1 |
| Muggia, FM | 1 |
| Tangen, CM | 1 |
| Ardalan, B | 1 |
| Doroshow, JH | 1 |
| Meyers, FJ | 1 |
| Holcombe, RF | 1 |
| Weiss, GR | 1 |
| Mangalik, A | 1 |
| Vokes, EE | 1 |
| Drinkard, LC | 1 |
| Samuels, BL | 1 |
| Hoffman, PC | 1 |
| Watson, S | 1 |
| Bitran, JD | 1 |
| Haraf, DJ | 1 |
| Ferguson, MF | 1 |
| Golomb, HM | 1 |
| Grem, JL | 1 |
| McAtee, N | 1 |
| Murphy, RF | 1 |
| Hamilton, JM | 1 |
| Balis, F | 1 |
| Steinberg, S | 1 |
| Arbuck, SG | 1 |
| Setser, A | 1 |
| Jordan, E | 1 |
| Chen, A | 1 |
| Kogut, MH | 1 |
| Tellez, G | 1 |
| Hargis, BM | 1 |
| Corrier, DE | 1 |
| DeLoach, JR | 1 |
| Dranitsaris, G | 1 |
| Tran, TM | 1 |
| Elias, L | 1 |
| Blumenstein, BA | 1 |
| Kish, J | 1 |
| Flanigan, RC | 1 |
| Wade, JL | 1 |
| Lowe, BA | 1 |
| Goodwin, JW | 1 |
| Crawford, ED | 1 |
| Crawford, J | 1 |
| O'Rourke, M | 1 |
| Schiller, JH | 1 |
| Spiridonidis, CH | 1 |
| Yanovich, S | 1 |
| Ozer, H | 1 |
| Langleben, A | 1 |
| Hutchins, L | 1 |
| Koletsky, A | 1 |
| Clamon, G | 1 |
| Burman, S | 1 |
| White, R | 1 |
| Hohneker, J | 1 |
| Spiridonitis, CH | 1 |
| Scheithauer, W | 2 |
| Kornek, G | 1 |
| Marczell, A | 2 |
| Salem, G | 1 |
| Karner, J | 2 |
| Kovats, E | 1 |
| Burger, D | 1 |
| Greiner, R | 1 |
| Pidlich, J | 1 |
| Schneeweiss, B | 1 |
| Raderer, M | 1 |
| Rosen, H | 1 |
| Depisch, D | 2 |
| Tepper, JE | 1 |
| O'Connell, MJ | 1 |
| Petroni, GR | 1 |
| Hollis, D | 1 |
| Cooke, E | 1 |
| Benson, AB | 1 |
| Cummings, B | 1 |
| Gunderson, LL | 1 |
| Martenson, JA | 1 |
| Saltz, LB | 1 |
| Kemeny, NE | 1 |
| Tong, W | 1 |
| Harrison, J | 1 |
| Berkery, R | 1 |
| Kelsen, DP | 1 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 1 |
| Monaco, F | 1 |
| Einhorn, LH | 1 |
| Hietanen, P | 1 |
| Teerenhovi, L | 1 |
| Joensuu, H | 1 |
| Hudes, GR | 1 |
| Lipsitz, S | 1 |
| Grem, J | 1 |
| Morrisey, M | 1 |
| Weiner, L | 1 |
| Kugler, JW | 1 |
| Benson, A | 1 |
| Kornek, GV | 1 |
| Schratter-Sehn, A | 1 |
| Krauss, G | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Locker, G | 1 |
| Paridaens, R | 1 |
| Uges, DR | 1 |
| Barbet, N | 1 |
| Choi, L | 1 |
| Seeghers, M | 1 |
| van der Graaf, WT | 1 |
| Groen, HJ | 1 |
| Dumez, H | 1 |
| Buuren, IV | 1 |
| Muskiet, F | 1 |
| Capdeville, R | 1 |
| Oosterom, AT | 1 |
| de Vries, EG | 1 |
| Au, E | 1 |
| Koo, WH | 1 |
| Lee, KS | 1 |
| Chua, EJ | 1 |
| Soo, KC | 1 |
| Seow-Choen, F | 1 |
| Low, CH | 1 |
| Ng, BK | 1 |
| Hoe, M | 1 |
| Bartolucci, A | 1 |
| Vogel, C | 1 |
| Windle, R | 1 |
| Macpherson, S | 1 |
| Bell, PR | 1 |
| Pazdur, R | 1 |
| Ajani, JJ | 1 |
| Abbruzzese, JL | 1 |
| Belt, RJ | 1 |
| Dakhil, SR | 1 |
| Dubovsky, D | 1 |
| Graham, S | 1 |
| Pilat, S | 1 |
| Winn, R | 1 |
| Levin, B | 1 |
| Petruzzelli, GJ | 1 |
| Johnson, JT | 1 |
| de Vries, EJ | 1 |
| Shimamura, M | 1 |
| Takigawa, T | 1 |
| Urabe, A | 1 |
| Okabe, T | 1 |
| Souza, LM | 1 |
| Takaku, F | 1 |
| Uzuka, Y | 1 |
| Saito, Y | 1 |
| Takahashi, H | 1 |
| Komatsu, M | 1 |
| Ito, T | 1 |
| McIntyre, KW | 1 |
| Unowsky, J | 1 |
| DeLorenzo, W | 1 |
| Benjamin, W | 1 |
| Amadori, S | 1 |
| Guglielmi, C | 1 |
| Anselmo, AP | 1 |
| Cimino, G | 1 |
| Ruco, LP | 1 |
| Papa, G | 1 |
| Biagini, C | 1 |
| Mandelli, F | 1 |
1 review available for fluorouracil and Agranulocytosis
| Article | Year |
|---|---|
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
19 trials available for fluorouracil and Agranulocytosis
| Article | Year |
|---|---|
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot | 2005 |
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a | 1984 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Drug Administration Schedule; Female; Fluorouracil; Ga | 1994 |
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Antineo | 1996 |
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Topics: Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dise | 1997 |
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resist | 1997 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; | 1999 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2000 |
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Agranulocytosis; Amidines; Antimetabolites, Antineopl | 2000 |
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1977 |
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dru | 1992 |
19 other studies available for fluorouracil and Agranulocytosis
| Article | Year |
|---|---|
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2008 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2011 |
[Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal Candida albicans infection in experimental granulocytopenic mice].
Topics: Adjuvants, Immunologic; Administration, Oral; Agranulocytosis; Animals; Basidiomycota; Candidiasis; | 2003 |
Toxicity studies of 5-fluorouracil used as an adjunct to surgery.
Topics: Agranulocytosis; Fluorouracil; Humans; Leukopenia; Surgical Procedures, Operative; Uracil | 1960 |
STUDIES ON THE LYMPHOCYTE RESPONSE TO INFLAMMATION.
Topics: Agranulocytosis; Aminopterin; Animals; Azaguanine; Biopsy; Chloramphenicol; Connective Tissue; Cyclo | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
Mechanisms of levamisole-induced granulocytopenia in breast cancer patients.
Topics: Acute Disease; Adult; Aged; Agranulocytosis; B-Lymphocytes; Breast Neoplasms; Colony-Forming Units A | 1980 |
Successful treatment of sorivudine-related agranulocytosis with granulocyte-colony stimulating factor.
Topics: Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Antiviral Agents; Arabinofuranosyluracil; Fe | 1995 |
The effect of 5-fluorouracil treatment of chicks: a cell depletion model for the study of avian polymorphonuclear leukocytes and natural host defenses.
Topics: Agranulocytosis; Animals; Chickens; Dose-Response Relationship, Drug; Fluorouracil; Lymphocyte Deple | 1993 |
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bre | 1995 |
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 1999 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
Neutropenia associated with metronidazole.
Topics: Agranulocytosis; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Metronidazole; | 1979 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Synergistic effect of dolichyl phosphate and human recombinant granulocyte colony-stimulating factor on recovery from neutropenia in mice treated with anti-cancer drugs.
Topics: Agranulocytosis; Animals; Antineoplastic Agents; Colony-Stimulating Factors; Dolichol Phosphates; Do | 1988 |
[Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy].
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1989 |
Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha.
Topics: Adjuvants, Immunologic; Agranulocytosis; Animals; Bacterial Infections; Bone Marrow; Cyclophosphamid | 1989 |
Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP).
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1985 |